UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Globe Newswire•03/11/2026•08:00 ET
0
Key Highlights
- ➤UroGen will present at Guggenheim Securities’ healthcare innovation conference November 10, 2026
- ➤Presentation includes a fireside chat and one-on-one investor meetings
- ➤UroGen has two approved products treating distinct urothelial cancer indications
- ➤RTGel technology is designed to extend urinary-tract medication exposure
PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Guggenheim Securities 3(rd) Annual Healthcare Innovation Conference, to take place November 9-11, 2026.
The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 90 days.
Get started
Create a free account to read the full story.